• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

左旋多巴控释制剂(息宁控释片)的体内行为特征

Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR).

作者信息

Wilding I R, Hardy J G, Davis S S, Melia C D, Evans D F, Short A H, Sparrow R A, Yeh K C

机构信息

Pharmaceutical Profiles Limited, Nottingham, England.

出版信息

Clin Neuropharmacol. 1991 Aug;14(4):305-21. doi: 10.1097/00002826-199108000-00003.

DOI:10.1097/00002826-199108000-00003
PMID:1913698
Abstract

The gastrointestinal transit and systemic absorption of Sinemet CR (50-200) controlled-release tablets and standard Sinemet (25-100) immediate-release (IR) tablets have been studied in fasted and fed healthy human subjects. Both formulations were labelled with a gamma-emitting radionuclide and their gastric emptying, colon arrival and in vivo disintegration profiles monitored using gamma scintigraphy. The IR dosage forms were found to disperse soon after administration and to empty rapidly from both fasted and fed stomachs. Erosion of the CR system was independent of food or stomach pH. The CR tablet was observed to disintegrate fully in the gastrointestinal (GI) tract, resulting in complete release of levodopa over a 3-4 h time period. Considerable intersubject variation was found to exist for levodopa absorption. Absorption was more protracted with Sinemet CR than with standard Sinemet, due to the controlled release characteristics of the tablet matrix. There was no rapid initial absorption phase and instead, a gradual build-up in the absorption profile occurred.

摘要

已在禁食和进食的健康人体受试者中研究了息宁控释片(50-200)和标准息宁速释片(25-100)的胃肠道转运及全身吸收情况。两种制剂均用发射γ射线的放射性核素标记,并使用γ闪烁显像法监测其胃排空、结肠到达及体内崩解情况。发现速释剂型给药后很快分散,并从禁食和进食的胃中迅速排空。控释系统的侵蚀与食物或胃内pH值无关。观察到控释片在胃肠道完全崩解,导致左旋多巴在3-4小时内完全释放。发现左旋多巴吸收存在相当大的个体间差异。由于片剂基质的控释特性,息宁控释片的吸收比标准息宁更为持久。没有快速的初始吸收阶段,相反,吸收曲线呈逐渐上升趋势。

相似文献

1
Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR).左旋多巴控释制剂(息宁控释片)的体内行为特征
Clin Neuropharmacol. 1991 Aug;14(4):305-21. doi: 10.1097/00002826-199108000-00003.
2
Gastrointestinal transit of Sinemet CR in healthy volunteers.健康志愿者中息宁控释片的胃肠道转运情况。
Neurology. 1989 Nov;39(11 Suppl 2):53-8.
3
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.息宁控释片的药代动力学和生物利用度:人体研究综述
Neurology. 1989 Nov;39(11 Suppl 2):25-38.
4
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.控释左旋多巴/卡比多巴25/100(息宁控释片25/100):未经治疗的帕金森病患者的药代动力学和临床疗效
Clin Neuropharmacol. 1994 Oct;17(5):429-34. doi: 10.1097/00002826-199410000-00005.
5
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).息宁控释片(50/200)与标准息宁(25/100)的药代动力学和药效学比较。
Neurology. 1989 Nov;39(11 Suppl 2):38-44; discussion 59.
6
Pharmaceutical design and development of a Sinemet controlled-release formulation.左旋多巴/卡比多巴控释制剂的药物设计与开发
Neurology. 1989 Nov;39(11 Suppl 2):20-4.
7
The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Clin Neurol Neurosurg. 1993 Sep;95(3):215-9. doi: 10.1016/0303-8467(93)90126-2.
8
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.左旋多巴控释制剂的比较多剂量药代动力学
Eur Neurol. 1992;32(6):343-8. doi: 10.1159/000116858.
9
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.控释卡比多巴/左旋多巴(息宁50/200 CR4):临床和药代动力学研究。
Neurology. 1989 Nov;39(11 Suppl 2):45-53; discussion 59.
10
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).卡比多巴-左旋多巴口服缓释胶囊制剂(IPX066)与速释卡比多巴-左旋多巴(息宁(®))、缓释卡比多巴-左旋多巴(息宁(®)控释片)以及卡比多巴-左旋多巴-恩他卡朋(珂丹(®))的药代动力学比较。
J Clin Pharmacol. 2015 Sep;55(9):995-1003. doi: 10.1002/jcph.514. Epub 2015 May 20.

引用本文的文献

1
The "Wearing Off" Phenomenon for Rasagiline, Entacapone, Carbidopa, and Levodopa in the Setting of Parkinson's Disease.雷沙吉兰、恩他卡朋、卡比多巴和左旋多巴在帕金森病中的“疗效减退”现象
HCA Healthc J Med. 2025 Feb 1;6(1):71-74. doi: 10.36518/2689-0216.1718. eCollection 2025.
2
Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.基于模型的帕金森病左旋多巴控释制剂的优化。
Sci Rep. 2023 Sep 22;13(1):15869. doi: 10.1038/s41598-023-42878-5.
3
How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
如何优化帕金森病治疗的效果和安全性?——药物与食物和膳食补充剂相互作用的系统评价。
Curr Neuropharmacol. 2022;20(7):1427-1447. doi: 10.2174/1570159X19666211116142806.
4
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?帕金森病的运动和非运动并发症:是否需要持续药物输送?
J Neural Transm (Vienna). 2013 Sep;120(9):1305-20. doi: 10.1007/s00702-013-0981-5. Epub 2013 Mar 2.
5
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.帕金森病治疗中的药代动力学优化:最新进展
Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001.
6
Pharmacokinetic optimisation in the treatment of Parkinson's disease.帕金森病治疗中的药代动力学优化
Clin Pharmacokinet. 1996 Jun;30(6):463-81. doi: 10.2165/00003088-199630060-00004.
7
Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.非洛地平缓释片的吸收、胃肠道转运及片剂溶蚀
Pharm Res. 1993 May;10(5):709-14. doi: 10.1023/a:1018959732744.
8
Pharmacokinetic considerations in gastrointestinal motor disorders.胃肠运动障碍中的药代动力学考量
Clin Pharmacokinet. 1995 Jan;28(1):41-66. doi: 10.2165/00003088-199528010-00005.
9
Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.γ闪烁扫描术在药物剂型评价中的应用
Eur J Nucl Med. 1992;19(11):971-86. doi: 10.1007/BF00175865.